Oral NAloxone to overcome the moRphine effect in acute COronary syndrome patients treated with TICagrelor - NARCOTIC trial.
Piotr NiezgodaMalwina A BarańskaJoanna SikoraPrzemysław SobczakKatarzyna BuszkoAdam SikoraMichał P MarszałłEliano P NavareseBernd JilmaJacek KubicaPublished in: Cardiology journal (2020)
To conclude, this trial shows that naloxone co-administration in ticagrelor-treated acute coronary syndrome patients on concomitant treatment with morphine shows no definite superiority in terms of ticagrelor pharmacokinetic and pharmacodynamic profile.
Keyphrases
- acute coronary syndrome
- percutaneous coronary intervention
- antiplatelet therapy
- newly diagnosed
- end stage renal disease
- study protocol
- phase iii
- clinical trial
- ejection fraction
- st segment elevation myocardial infarction
- phase ii
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- patient reported
- double blind